Drugs / Vidutolimod
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05445609 | Jun 2023 → Jun 2027 | prostate adenocarcinoma | Emory University | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04916002 | Nov 2021 → Oct 2024 | cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, oropharynx squamous cell carcinoma, skin basal cell carcinoma +2 | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04401995 | Sep 2020 → Aug 2024 | melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06063746 | — | refractory malignant neoplasm | Regeneron Pharmaceuticals | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-15 | XOMA (US) LLC | XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences xoma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vidutolimod | “Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR9) agonist, with the ability to generate tumor-targeted T cells capable of killing a tumor both locally and systemically in...” NCT05445609 ↗ |
| Known as | CMP-001 | “patients receiving either neoadjuvant Vidutolimod (CMP-001)/nivolumab or neoadjuvant nivolumab.” NCT04401995 ↗ |
| Action | Activate | “Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR9) agonist” NCT05445609 ↗ |
| Route | Subcutaneous | “Vidutolimod 5mg subcutaneous 1st dose” NCT04401995 ↗ |